Company Leadership

A seasoned executive who joined Bridge to Life^™ in January 2022, Don has a proven track record and excels in spearheading companies through diverse and challenging business environments. Specializing in strategic planning and execution across startups, turnarounds, and high-growth scenarios, Don’s leadership style is characterized by a hands-on approach and a relentless drive for results. Having held leadership positions in both small startups and large corporations, Don possesses a deep understanding of business dynamics and a keen ability to drive innovation and sustainable growth. With extensive experience spanning various sectors including cardiology, thoracic surgery, biologics, and robotics, Don has consistently delivered exceptional outcomes, and has already advanced Bridge to Life^™ in his two-year leadership tenure.
Notable accomplishments include CEO of SynCardia Systems, LLC, which led to a successful turnaround and sale of the company, highlighted by impactful restructuring and strategic initiatives. His management experience includes Novoste, Ekos, Abiomed, CR Bard and Cordis Corporation. Don also served in the United States Air Force and received his bachelor’s degree in Industrial Engineering Technology from the State University of New York and MBA from Nova Southeastern University.
Committed to knowledge sharing, Don actively engages in teaching and speaking engagements worldwide.
+ –

Mr. Lenz’s financial and operational leadership experience over the past 20 years includes serving as a public company Chief Financial Officer and Chief Operating Officer for several life science and medical device companies, completing numerous financings, comprised of public and private equity, credit agreements and IPOs, raising an aggregate of $1 billion. During his career, Mr. Lenz has negotiated multiple credit facilities, strategic transactions, licensing and collaboration agreements, while ensuring SEC and SOX compliance.
Most recently, Mr. Lenz served as the Executive Vice President, Chief Financial Officer of ADMA Biologics and General Manager of its subsidiary business unit, ADMA BioCenters. Joining ADMA Biologics in May 2012, Mr. Lenz was instrumental in the Company’s IPO and Nasdaq listing along with co-leading the acquisition of its contract manufacturer. As part of the acquisition, Mr. Lenz was responsible for integrating all financial reporting and financial operations, as well as ensuring the seamless integration of all human resource activities and information technology systems. The acquisition transformed the company from a development stage to a commercial organization, with three FDA approved products, achieving multiple product launches, resulting in corporate profitability.
Mr. Lenz is also the finance committee co-chairperson for BioNJ.
Prior to his CFO roles, Mr. Lenz was a Corporate Controller of Smiths Detection, and previously was a senior auditor at KPMG LLP.
Mr. Lenz received a B.S. from Rider University, an M.B.A. from Saint Joseph’s University and is a licensed Certified Public Accountant in New Jersey.

+ –

Mr. Castiglioni has three decades of senior leadership experience in healthcare, medtech, and biotechnology. Mr. Castiglioni has been particularly effective in building high-performing commercial teams, scaling early-stage ventures into global businesses, and driving transformative growth. Most notably, during his tenure at Intuitive Surgical, one of medtech’s most notable success stories, he built and led commercial teams that drove adoption of the da Vinci surgical system, helping to establish the company as a market leader. He has since served as CCO at Hyperfine, MediGO (acquired by CareDx), and Siren Care, where he consistently delivered rapid revenue growth and successful go-to-market strategies across the U.S., Europe, and Asia-Pacific.

Mauricio Carvalho is a BSN, RN, MBA with advanced degrees in Critical Care Nursing and Dialysis. He has 25 years of clinical experience and has co-authored multiple peer-reviewed publications on Ex Vivo Organ Perfusion. He has held positions at Vital Therapies Inc. and Aerogen Inc.

Blago Herrera is a medtech veteran with over 30 years of experience in the industry, including roles at Johnson and Johnson, Abiomed, Novoste Corporation, and most recently, held the title VP of Quality at SynCardia Systems. He has expertise in manufacturing, supply chain, quality, and regulatory affairs, and has built several manufacturing facilities from the ground up.

Kurt Cannon brings nearly 25 years of MedTech commercial leadership experience to Bridge to Life™, with a background that spans marketing, sales, corporate accounts, operations, and general management. He has spent his career helping healthcare technology organizations turn strategy into execution, build strong commercial teams, and bring important products to market in highly specialized clinical environments.

Before joining Bridge to Life™, Kurt served as Vice President of Endoscopy Marketing at Olympus Corporation of the Americas, where he led marketing for a broad GI endoscopy capital and disposable portfolio and partnered closely across sales, clinical, strategy, regulatory, legal and commercial operations. Prior to Olympus, he held multiple leadership roles with Fujifilm Healthcare Americas and was part of the team that helped build and scale its U.S. GI endoscopy business in its early years. Kurt also brings five years of digital agency experience from Liquid Marketing, adding perspective in brand development, digital engagement, and customer-focused marketing execution.

Known as a culture-driven leader, Kurt believes growth is built through clear direction, strong teams, and disciplined execution. His approach is practical, collaborative, and grounded in staying close to customers while creating the conditions for people to do their best work. In his role at Bridge to Life™, Kurt is focused on advancing the company’s global marketing strategy, strengthening the overall brand, and helping lead the next stage of growth.

Baha El Mahgoub holds a BSc in Clinical Pharmacy and has over 20 years of business management experience in the pharmaceutical and medical equipment industries. He has expertise in building and expanding early-stage companies in international markets, with a focus on sales, marketing, and service operations.

Stephanie Cranford is a Human Resources executive with more than 15 years of experience scaling organizations and leading global people operations across high-growth, healthcare, manufacturing, and Fortune 500 work environments. She specializes in organizational design, workforce strategy, compensation, and operational infrastructure within complex and highly regulated industries. Stephanie has partnered closely with executive leadership teams to support organizational growth, international expansion, and business transformation initiatives across the United States and Europe.

Stephanie earned a Bachelor of Business Administration in Management from University of Georgia and holds both PHR and SHRM-CP certifications.

Jennifer Guzman has 30 years of experience across MedTech including biotech, diagnostics and healthcare systems. Recently Jennifer served as Vice President of Marketing at Vital Therapies where she led all commercialization activities for a combination orphan cellular therapy device for acute liver failure. Jennifer earned her bachelor’s degree from the University of California at San Diego, and an MBA with a marketing specialization from San Diego State University.

Chriss Stanford holds a BA and MA in the medical sciences and has over 20 years of experience in clinical research and development, including his prior role at Terumo BCT. He has expertise in clinical operations, regulatory affairs and data management, analysis and reporting through all phases of medical device, pharmaceuticals, and combination products development.

Board

Currently, Mr. Gill serves on the boards of two public companies: Y-mAbs Therapeutics (YMAB), an immuno-oncology company focused on pediatric brain cancer, and Evolus (EOLS), an aesthetics company. In addition, he serves on the boards of several private companies including as the Chairman of Healthtronics, Inc, a mobile surgical equipment company. Mr. Gill’s other private company boards include RapidPulse, Inc., an ischemic stroke medical device company, Bridge to Life^™ Ltd, a leading company in the organ transplantation market and Perimetrics AI, a dental diagnostic company.
In his most recent operating role Mr. Gill joined Endochoice (NYSE: GI) in August 2014 as CFO, executed its IPO in June 2015, and then later assumed the added roles of President and Chief Operating Officer in March 2016. EndoChoice was a 500-employee public medical device company with operations in US, Germany and Israel. Boston Scientific acquired Endochoice in November 2016, at which point Mr. Gill retired.
Earlier in his career Mr. Gill served in a variety of senior leadership roles (president, COO and CFO) for several medical device companies, including TransEnterix, NxStage Medical, CTI Molecular Imaging, Novoste Corporation and Dornier Medical.
Mr. Gill has led the IPO’s of four companies, has sold four public companies, and has raised more than $1.3 Billion in equity and debt during his career. He graduated with cum laude honors from Wake Forest University with a B.S. in Accounting and earned an MBA (with distinction) from Emory University.
+ –

Don Webber

A seasoned executive who joined Bridge to Life^™ in January 2022, Don has a proven track record and excels in spearheading companies through diverse and challenging business environments. Specializing in strategic planning and execution across startups, turnarounds, and high-growth scenarios, Don’s leadership style is characterized by a hands-on approach and a relentless drive for results. Having held leadership positions in both small startups and large corporations, Don possesses a deep understanding of business dynamics and a keen ability to drive innovation and sustainable growth. With extensive experience spanning various sectors including cardiology, thoracic surgery, biologics, and robotics, Don has consistently delivered exceptional outcomes, and has already advanced Bridge to Life^™ in his two-year leadership tenure.
Notable accomplishments include CEO of SynCardia Systems, LLC, which led to a successful turnaround and sale of the company, highlighted by impactful restructuring and strategic initiatives. His management experience includes Novoste, Ekos, Abiomed, CR Bard and Cordis Corporation. Don also served in the United States Air Force and received his bachelor’s degree in Industrial Engineering Technology from the State University of New York and MBA from Nova Southeastern University.
Committed to knowledge sharing, Don actively engages in teaching and speaking engagements worldwide.
+ –